BioWorld MedTech

Sep. 22, 2016

Analysts sift through Abbott unit sale to find read-through for contested Alere deal

Abbott Laboratories' divestiture of its optics business could indicate that the company is ready to bite the figurative Alere Inc. bullet and move forward with that $5.8 billion acquisition – but not necessarily. Read More

Califf says combo products 'on my mind,' along with cross-center coordination

Spirox's Latera absorbable nasal implant technology demonstrates significant quality of life improvement

Weak clinical trial data in China leads to a rush of device withdrawals

Financings

Appointments and advancements

Product briefs

MDD's Oncology Extra

Today's news in brief

BioWorld

BioWorld briefs for May 22, 2026.

Acid alpha-glucosidase molecular structure isolated on black

‘Detargeted’ targeted gene therapy improves activity in Pompe

BioWorld

A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...

Roche reports new TREM2 agonists

BioWorld Science

F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...

Sangamo presents primate data for prion suppressor ST-506

BioWorld Science

Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...

Genescience presents STAT6 degrader for atopic dermatitis

BioWorld Science

Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....